CAR T-Cell Therapy Market to Surpass Valuation of USD 106.06 Billion by 2031 SkyQuest Technology
ZYME Stock | USD 13.95 0.55 3.79% |
About 72% of Zymeworks Common's investor base is looking to short. The analysis of the overall investor sentiment regarding Zymeworks Common Stock suggests that many traders are alarmed. The current market sentiment, together with Zymeworks Common's historical and current headlines, can help investors time the market. In addition, many technical investors use Zymeworks Common Stock stock news signals to limit their universe of possible portfolio assets.
Zymeworks |
Rising incidence of cancer around the world is projected to primarily augment the demand for CAR T-cell therapy therapy over the coming years.Westford, USA, Nov. 18, 2024 -- CAR T-Cell Therapy Market size was valued at USD 7.27 billion in 2023 to USD 106.06 billion by 2031, growing at a CAGR of .80 percent during the forecast period . Due to its extraordinary efficacy in combating hematological malignancies such as non-Hodgkins l
Read at finance.yahoo.com
Zymeworks Common Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Zymeworks Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Zymeworks Common Fundamental Analysis
We analyze Zymeworks Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zymeworks Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zymeworks Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Zymeworks Common is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Zymeworks Common Stock Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zymeworks Common stock to make a market-neutral strategy. Peer analysis of Zymeworks Common could also be used in its relative valuation, which is a method of valuing Zymeworks Common by comparing valuation metrics with similar companies.
Peers
Zymeworks Common Related Equities
TERN | Terns Pharmaceuticals | 3.41 | ||||
MRSN | Mersana Therapeutics | 3.04 | ||||
BLUE | Bluebird Bio | 2.44 | ||||
CYTK | Cytokinetics | 1.74 | ||||
SNDX | Syndax Pharmaceuticals | 0.48 | ||||
TVTX | Travere Therapeutics | 0.97 | ||||
ARWR | Arrowhead Pharmaceuticals | 1.03 | ||||
BPMC | Blueprint Medicines | 1.12 | ||||
PRQR | ProQR Therapeutics | 1.61 | ||||
DAWN | Day One | 1.81 | ||||
APLS | Apellis Pharmaceuticals | 2.23 | ||||
ALEC | Alector | 3.09 | ||||
AKRO | Akero Therapeutics | 3.94 | ||||
PTGX | Protagonist Therapeutics | 4.65 | ||||
STOK | Stoke Therapeutics | 5.30 | ||||
ANNX | Annexon | 5.31 | ||||
RLAY | Relay Therapeutics | 6.00 | ||||
INZY | Inozyme Pharma | 6.09 | ||||
RVMD | Revolution Medicines | 6.89 | ||||
ZNTL | Zentalis Pharmaceuticals | 8.20 | ||||
EDIT | Editas Medicine | 9.59 | ||||
YMAB | Y MAbs | 10.35 | ||||
CABA | Cabaletta Bio | 13.80 |
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |